BUFFALO, N.Y. (WIVB) — A new approach regarding stem-cell transplants has resulted in “exceptionally high” one-year overall survival rates for patients, Roswell Park Comprehensive Cancer Center ...

FDA authorized Tregzi for adults with acute leukemia, MDS, and other hematologic malignancies receiving closely matched donor ...

When a patient needs a stem cell transplant, finding a registered donor is only the first step. Some potential donors drop out before confirmatory typing, reducing the pool from which doctors can ...

When a patient needs a stem cell transplant, finding a registered donor is only the first step. Some potential donors drop out before confirmatory typing, reducing the pool from which doctors can ...

The FDA has approved an allogeneic regulatory T cell immunotherapy for use in matched-donor hematopoietic stem cell transplantation in patients with blood cancers, to improve survival for chronic ...

Orca-T integrates HSPCs for reconstitution, highly purified Tregs for GVHD suppression, and Tcons to accelerate immune recovery and preserve graft-versus-leukemia activity via a matched-donor, patient ...

Regulatory T cell-based immunotherapy approved for use in matched-donor HSCTs ...

In a phase 1b trial, subretinal delivery of a human stem cell-derived retinal pigment epithelium yielded visual improvements in patients with advanced geographic atrophy, according to a speaker.“This ...

(HSCT) following U.S. FDA approval of Tregzi, a first-of-its-kind, personalized cell therapy. Previously known as Orca-T, Tregzi is indicated for use in matched-donor HSCT with myeloablative ...

THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW Washington, DC 20001 This activity was supported by contracts from the National Institutes of Health (Sponsor Award ...